Bendamustine

Bendamustine2DCSD

Bendamustine is a chemotherapy medication used in the treatment of certain types of cancer. It is classified as an alkylating agent and is primarily used to treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Bendamustine is known for its unique mechanism of action, which combines properties of both alkylating agents and antimetabolites.

Medical Uses

Bendamustine is indicated for the treatment of:

• Chronic lymphocytic leukemia (CLL)
• Non-Hodgkin lymphoma (NHL), particularly in patients who have not responded to other treatments

Mechanism of Action

Bendamustine works by causing DNA damage in cancer cells, which leads to cell death. It forms cross-links between DNA strands, preventing the cancer cells from dividing and growing. This dual mechanism of action, involving both alkylation and antimetabolite activity, makes bendamustine effective against cancer cells that may be resistant to other treatments.

Administration

Bendamustine is administered intravenously. The dosage and treatment schedule depend on the type of cancer being treated, the patient's overall health, and other factors. It is typically given in cycles, with periods of treatment followed by periods of rest.

Side Effects

Common side effects of bendamustine include:

• Nausea
• Vomiting
• Fatigue
• Fever
• Infections due to lowered white blood cell counts
• Anemia
• Thrombocytopenia

Serious side effects can include severe infections, allergic reactions, and secondary cancers.

History

Bendamustine was first synthesized in the 1960s in the former East Germany. It was approved for medical use in the United States by the Food and Drug Administration (FDA) in 2008.

Research

Ongoing research is exploring the use of bendamustine in combination with other chemotherapy agents and targeted therapies to improve outcomes for patients with various types of cancer.

See Also

• Chemotherapy
• Chronic lymphocytic leukemia
• Non-Hodgkin lymphoma
• Alkylating agent
• Antimetabolite